TELO — Telomir Pharmaceuticals, Inc.

Is TELO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Telomir Pharmaceuticals, Inc. (TELO) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.48. The rating moved from Oversold to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Telomir Pharmaceuticals appears to trade as a thinly traded microcap biotech with limited public financial disclosures and no visible social or research momentum. The name faces high binary clinical/regulatory risk and significant dilution and liquidity uncertainty common to small biopharma issuers. Broader sector flows show investor preference for large-cap defensive pharma, which reduces near-term capital available to tiny specialty issuers. Absent clear upcoming positive clinical data, partnership announcements, or transparent financials, the company is exposed to sharp downside from funding needs or negative clinical/regulatory news. Monitoring for any filing updates, cash runway disclosures, or definitive clinical catalysts is essential before revising outlook.

Key factors

  • Microcap/penny-stock status with limited public financial disclosure and no recent EDGAR comparisons provided
  • High likelihood of limited liquidity and elevated intraday volatility for TELO shares
  • Biotech/clinical-stage profile implies binary clinical and regulatory catalysts that can move the stock sharply
  • Sector flows currently favor large-cap pharma defensives, reducing risk‑on capital available to small-cap biotechs
  • Convertible-debt and broader biotech dilution theme raising funding/dilution risks across the group
  • No visible social sentiment or analyst coverage to support near-term positive momentum

Risks

  • Severe dilution or equity raises if cash runway is short (common for small biotechs)
  • Adverse clinical trial results or regulatory setbacks that could materially reduce valuation
  • Very low trading liquidity leading to wide spreads, price manipulation risk, and outsized moves on small orders
  • Lack of transparent financial reporting or recent filings increases informational asymmetry
  • Sector rotation into large-cap defensive pharmaceuticals could further reduce investor interest
  • Macro or funding market stress that tightens access to capital for microcap issuers
  • Unexpected legal, IP, or partnership disruptions given limited public disclosure

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for TELO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.